The results of transplantation are more and more better.
New medicines are discovered and contribute to these performances.
I present you a future challenge: anti-CD40 antibodies, very effective in phase 1 clinical trials.
The molecule is able to inhibate the presentation of antigens to the immune system, owing to reduce the risks of graft rejection
